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A B S T R A C T
Objective: The aim of this study was to evaluate the eﬀect of melatonin supplementation on mental health
parameters, metabolic and genetic parameters in women suﬀering from polycystic ovary syndrome (PCOS).
Methods: This randomized, double-blinded, placebo-controlled clinical trial was performed on 58 subjects, aged
18–40 years old. Subjects were randomly allocated to take either 10mg melatonin (2 melatonin capsules, 5 mg
each) (n=29) or placebo (n=29) once a day 1 h before bedtime for 12 weeks. Glycemic control and lipid
proﬁles were measured at baseline and after the 12-week intervention. Using RT-PCR method, gene expression
related to insulin and lipid metabolism was conducted on peripheral blood mononuclear cells (PBMCs) of PCOS
women.
Results: Melatonin supplementation signiﬁcantly decreased Pittsburgh Sleep Quality Index (β −2.15; 95% CI,
−3.62,−0.68; P=0.005), Beck Depression Inventory index (β−3.62; 95% CI,−5.53,−1.78; P<0.001) and
Beck Anxiety Inventory index (β −1.95; 95% CI, −3.41, −0.48; P=0.01) compared with the placebo. In
addition, melatonin administration, compared with the placebo, signiﬁcantly reduced serum insulin (β −1.20
µIU/mL; 95% CI, −2.14, −0.26; P=0.01), homeostasis model of assessment-insulin resistance (HOMA-IR) (β
−0.28; 95% CI, −0.50, −0.05; P=0.01), serum total- (β −7.96mg/dL; 95% CI, −13.75, −2.17; P=0.008)
and LDL-cholesterol levels (β−5.88mg/dL; 95% CI,−11.42,−0.33; P=0.03), and signiﬁcantly increased the
quantitative insulin sensitivity check index (QUICKI) (β 0.008; 95% CI, 0.002, 0.014; P=0.007). Moreover,
melatonin supplementation upregulated gene expression of peroxisome proliferator-activated receptor gamma
(PPAR-γ) (P=0.004) and low-density lipoprotein receptor (LDLR) (P=0.01) compared with the placebo.
Conclusions: Overall, melatonin administration for 12 weeks had beneﬁcial eﬀects on mental health parameters,
insulin levels, HOMA-IR, QUICKI, total- and LDL-cholesterol levels, and gene expression of PPAR-γ and LDLR
among women with PCOS.
1. Introduction
Polycystic ovarian syndrome (PCOS) is the most common en-
docrinopathy that occurs in up to 10% of women during their re-
productive years (Casadei et al., 2018). It is characterized by hyper-
androgenism, ovulatory dysfunction and metabolic disturbances such
as dyslipidemia, insulin resistance, obesity, and increased inﬂammatory
markers (Antonio et al., 2018; Dumesic et al., 2019). Although the
etiology of PCOS is not yet fully understood, extensive evidence suggest
that insulin resistance plays a pivotal role in this condition
(Dumesic et al., 2019). Insulin resistance and impaired lipid proﬁles are
present in 50–75% and 70% of subjects with PCOS, respectively (Kahal
et al., 2018; Pluta et al., 2018). Both abnormalities are main compo-
nents of metabolic syndrome (MetS), and a major risk factor for car-
diovascular disease and type 2 diabetes mellitus (Anwar and Shikalgar,
2017; Gunning and Fauser, 2017). The majority of subjects with PCOS
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suﬀer from symptoms related to hyperandrogenism, including hir-
sutism, oligomenorrhea, acne, and androgenic alopecia (Franik et al.,
2018). Furthermore, people with PCOS have increased sleep disorders,
depression, and anxiety (Fernandez et al., 2018). The negative impacts
of these symptoms impair the quality of life in PCOS patients
(Chaudhari et al., 2018).
Melatonin is an indoleamine that regulates various important ac-
tions related to circadian rhythms, reproduction, and the sleep cycle
(Reiter et al., 2010). Environmental stress leads to a disturbance of
diurnal rhythm of corticosterone and melatonin levels (Yuan et al.,
2016). The favorable eﬀects of melatonin administration on oocyte
maturation and embryo development have been conﬁrmed by in vitro
and in vivo studies (Tamura et al., 2009, 2012). In addition, both an-
imal and human studies have demonstrated that melatonin intake may
have beneﬁcial eﬀects on components of MetS, including hypergly-
cemia and insulin resistance, increased blood pressure, dyslipidemia
and obesity (Peschke et al., 2010; Raygan et al., 2017). In addition,
epidemiologic studies displayed an inverse association between insulin
resistance and nocturnal melatonin secretion (McMullan et al., 2013).
Reduction in the intrafollicular melatonin levels and signiﬁcantly in-
creased excretion of 6-sulfatoxymelatonin, the main excretory meta-
bolite of melatonin, has been reported in patients with PCOS
(Spinedi and Cardinali, 2018). Normal melatonin concentrations in the
follicular ﬂuid are necessary for high oocyte quality, follicular growth,
and ovulation, whereas decreased follicular melatonin levels may be
responsible for poor quality of oocyte and anovulation in these patients
(Spinedi and Cardinali, 2018). In a recent randomized, controlled trial,
combined melatonin and myo-inositol administration, compared with
myo-inositol alone, signiﬁcantly improved oocyte and embryo quality
in PCOS patients who were candidates for in vitro fertilization (IVF)
(Pacchiarotti et al., 2016).
To our knowledge, no investigation is currently on-going to evaluate
the impact of melatonin supplementation on mental health parameters,
metabolic and genetic proﬁles in women with PCOS who candidates for
IVF. Therefore, the present study was done to investigate the eﬀects of
melatonin administration on mental health parameters, glycemic
homeostasis, lipid proﬁles and its related gene expression in these pa-
tients.
2. Materials and methods
2.1. Trial design and subjects
The current randomized, double-blinded, placebo-controlled trial,
registered in the Iranian website for registration of clinical trials
(http://www.irct.ir: IRCT2017090533941N23), was carried out among
58 women with PCOS aged 18–40 years old who were referred to the
Taleghani Hospital in Tehran, Iran, between December 2017 and July
2018. Diagnosis of PCOS was performed according to the Rotterdam
criteria (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus
Workshop Group, 2004): those with the two of the following criteria
were considered as having PCOS: oligo- and/or anovulation (deﬁned as
delayed menses >35 days or <8 spontaneous hemorrhagic episodes/
year), clinical (hirsutism using modiﬁed Ferriman-Gallwey score
of ≥ 8) and/or biochemical signs of hyperandrogenism and polycystic
ovaries (12 or more follicles in each ovary measuring 2–9mm in dia-
meter, and/or increased ovarian volume >10 ml3). The study protocol
was approved by the Ethics Committee of Shahid Beheshti University of
Medical Sciences (SBUMS). Written informed consent was obtained
from all participants prior to the intervention. Exclusion criteria were as
follows: pregnancy, adrenal hyperplasia, androgen-secreting tumors,
hyperprolactinemia, thyroid dysfunction, diabetes and other metabolic
disorders at enrollment, inﬂammatory and malignant diseases, those
taking melatonin supplements, antioxidant and/or anti-inﬂammatory
supplements within 3 months prior to the enrollment in the study, the
night shift workers.
2.2. Supplementation
Initially, patients were randomly divided into two groups to take
either 10mg melatonin (2 melatonin capsules, 5 mg each) (n=29) or
placebo (n=29) once a day 1 h before bedtime for 12 weeks.
Melatonin and its placebo were produced in the same capsule shape and
packaged by Zahravi Pharmaceutical Company (Tabriz, Iran) and Barij
Essence Pharmaceutical Company (Kashan, Iran), respectively. During
the study, the use of melatonin or placebo was examined by asking
subjects to return the medication containers and through brief daily cell
phone reminders to take the supplements. All subjects completed 3-day
diet recall at weeks 0, 3, 6, 9 and 12 of the intervention. Daily macro-
and micro-nutrient intakes were calculated by nutritionist IV software
(First Databank, San Bruno, CA).
2.3. Anthropometric measures
A trained staﬀ took anthropometric measurements in the clinic at
baseline and after the 12-week intervention. Height and weight (Seca,
Hamburg, Germany) were determined with light clothing and the shoes
removed. Body mass index (BMI) was calculated as weight (in kilo-
grams) divided by height (in meters) squared.
2.4. Assessment of outcomes
Glycemic control was considered as the primary outcome. Lipid
proﬁles, gene expression of peroxisome proliferator-activated receptor
gamma (PPAR-γ), glucose transporter 1 (GLUT-1) and low-density li-
poprotein receptor (LDLR) were recognized as the secondary outcomes.
2.5. Mental health parameters
Quality of sleep was determined using Pittsburgh Sleep Quality
Index (PSQI) (Buysse et al., 1989). Beck Depression Inventory index
(BDI) was assessed using a self-compiled questionnaire of 21 items in
multiple choice format (Beck et al., 1961). Anxiety was measured using
the Beck Anxiety Inventory (BAI)-21 questionnaire developed by Beck
et al. (Beck et al., 1988) to determine the frequency of anxiety symp-
toms in adults.
2.6. Biochemical assessment
Fasting blood samples were taken from participants (15mL) at
baseline and after the 12-week intervention. To determine fasting
plasma glucose (FPG) and lipid proﬁles, enzymatic kits (Pars Azmun,
Tehran, Iran) with inter- and intra-assay coeﬃcient variances (CVs)
below 5% were used. Serum insulin levels were assessed using an ELISA
kit (Monobind, California, USA) with the intra- and inter-assay CVs
below 6%. The homeostatic model assessment for insulin resistance
(HOMA-IR) and the quantitative insulin sensitivity check index
(QUICKI) were determined according to the suggested formulas
(Pisprasert et al., 2013).
2.7. Isolation of lymphocyte cells
Lymphocytes were extracted from blood samples of women with
PCOS with a 50% percoll (Sigma-Aldrich, Dorset, UK). Samples were
taken for cell count and viability testing using trypan blue, and RNA
and DNA extraction (Dunkley et al., 2008).
2.8. RNA extraction and real-time PCR
RNA extraction was performed with use of the RNX-plus kit
(Cinnacolon, Tehran, Iran). Following extraction of the total RNAs from
each sample, the RNA quantiﬁcation was evaluated with an UV spec-
trophotometer. Samples OD 260/280 ratio was standardized between
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1.7 and 2.1 showing no contamination for either protein or DNA
(Dunkley et al., 2008). The isolated RNA was reverse transcribed to
cDNA library using the moloney murine leukemia virus reverse tran-
scriptase (M-MLV RT). Gene expressions of PPAR-γ, GLUT-1 and LDLR
were evaluated by quantitative RT-PCR, using the LightCycler tech-
nology (Roche Diagnostics, Rotkreuz, Switzerland) with SYBR green
detection and Amplicon Kit (Table 1). Glyceraldehyde-3-phosphate
dehydrogenase primers were used as a housekeeping gene. To design
primers, Primer Express Software (Applied Biosystems, Foster City) and
Beacon designer software (Takaposizt, Tehran, Iran) were utilized.
Relative transcription levels were calculated using the methods of
Pﬀaﬁ.
2.9. Sample size
We used a randomized clinical trial sample size calculation formula
where type one (α) and type two errors (β) were 0.05, and 0.20
(power = 80%), respectively. Based on a previous trial (Raygan et al.,
2017), we used 2.20 as the SD and 1.75 as the change in mean (d) of
HOMA-IR as a primary outcome. Based on the formula, 25 subjects per
group treatment were needed; after allowing for 20% dropouts per each
group, the ﬁnal sample size was 30 subjects in each group.
2.10. Randomization
Randomization assignment was performed using computer-gener-
ated random numbers. Randomization and allocation were concealed
from the researchers and participants until the ﬁnal analyses were
completed. The randomized allocation sequence, enrolling participants
and allocating them to interventions were conducted by a trained staﬀ
at the clinic.
2.11. Statistical analyses
The Kolmogorov-Smirnov test was done to determine the normality
of data. Diﬀerences in anthropometric measures, dietary intakes and
gene expression related to insulin and lipid between treatment groups
were detected with independent-sample t-tests. Multiple linear regres-
sion models helped to assess the treatment eﬀects on study outcomes
after adjusting for confounding parameters including; age, and BMI.
Signiﬁcance of the treatment eﬀects was presented as the mean dif-
ferences with 95% conﬁdence interval. P-values <0.05 were con-
sidered statistically signiﬁcant. All statistical analyses were done using
the Statistical Package for Social Science version 18 (SPSS Inc., Chicago,
Illinois, USA).
3. Results
As demonstrated in the study ﬂow diagram (Fig. 1), during the
enrollment phase of the study, there were 64 women with PCOS;
however, 4 participants did not meet the inclusion criteria and thus
were excluded. During the follow-up, 2 participants dropped out of the
study due to personal reasons (one participant in each group). Finally,
58 participants [placebo (n=29) and melatonin (n=29)] completed
the trial.
Mean age, height, and baseline, end-of-trial and change body weight
and BMI were not statistically diﬀerent between the two groups
(Table 2).
Considering the 3-day dietary records obtained during the inter-
vention, there was no statistically signiﬁcant diﬀerence in terms of
dietary macro- and micro-nutrient intakes between melatonin and
placebo groups (Data not shown).
Melatonin supplementation signiﬁcantly decreased PSQI (β −2.15;
95% CI, −3.62, −0.68; P=0.005), BDI index (β −3.62; 95% CI,
−5.53, −1.78; P < 0.001) and BAI index (β −1.95; 95% CI, −3.41,
−0.48; P=0.01) compared with the placebo (Table 3). In addition,
melatonin administration, compared with the placebo, signiﬁcantly
reduced serum insulin (β −1.20 µIU/mL; 95% CI, −2.14, −0.26;
P=0.01), HOMA-IR (β −0.28; 95% CI, −0.50, −0.05; P=0.01),
serum total- (β−7.96mg/dL; 95% CI,−13.75,−2.17; P=0.008) and
LDL-cholesterol levels (β −5.88mg/dL; 95% CI, −11.42, −0.33;
P=0.03), and signiﬁcantly increased QUICKI (β 0.008; 95% CI, 0.002,
0.014; P=0.007). Melatonin supplementation did not aﬀect FPG and
other lipid proﬁles.
Melatonin supplementation upregulated gene expression of PPAR-γ
(1.14 ± 0.17-fold increase vs. 1.00 ± 0.15-fold change, P=0.004)
and LDLR (1.09 ± 0.13-fold increase vs. 0.98 ± 0.17-fold reduction,
P=0.01) compared with the placebo (Figs. 2 and 3).
Melatonin supplementation did not aﬀect gene expression of GLUT-
1 (1.08 ± 0.20-fold increase vs. 1.02 ± 0.18-fold increase, P=0.27)
compared with the placebo (Fig. 2).
4. Discussion
The current study is the ﬁrst report of the eﬀects of melatonin ad-
ministration on mental health parameters, metabolic and genetic pro-
ﬁles in women with PCOS. We found that melatonin supplementation
for 12 weeks to women with PCOS had favorable eﬀects on BDI, BAI,
PSQI index, insulin concentrations, HOMA-IR, QUICKI, and gene ex-
pression of PPAR-γ and LDLR, but did not aﬀect other metabolic pro-
ﬁles and gene expression of GLUT-1.
4.1. Eﬀects on mental health parameters
This study demonstrated that the intake of melatonin by patients
with PCOS for 12 weeks signiﬁcantly decreased BDI, BAI, and PSQI
index. Circadian rhythms have been documented to be signiﬁcantly
disrupted in people with depression (Germain and Kupfer, 2008). Sleep
disturbances such as early-morning awakening and insomnia are pro-
minent manifestations of depressed mood (Srinivasan et al., 2009),
indicating a close relationship between the melatonergic system and
clinical depression (Malhi and Kuiper, 2013; Srinivasan et al., 2009). In
addition, melatonin production from the pineal gland is modulated by
norepinephrine, suggesting a link been melatonin and mental health
disorders as well (Huang et al., 2015). Earlier, it was reported that
melatonin could be used as a potential candidate drug to improve the
neuropsychiatric behaviors via modulating the expression of the pro-
teins involved in anxiety and depression behaviors such as glutathione
S-transferase P 1 and complexin-1 (Nie et al., 2017). In agreement with
our ﬁndings, Ghaderi et al., al.(2018) showed that melatonin supple-
mentation to patients under methadone maintenance treatment for 12
weeks improved mental health parameters, including sleep quality,
anxiety, and depression indices. In another trial, melatonin consump-
tion at a daily dosage of 6mg for 6 weeks in children with atopic
dermatitis had a favorable impact on quality of sleep (Taghavi Ardakani
et al., 2018). In addition, Rahman et al., al.(2010) observed that
Table 1
Speciﬁc primers used for real-time quantitative PCR.
Gene Primer Product
size (bp)
Annealing
temperature (°C)
GAPDH F: AAGCTCATTTCCTGGTATGACAACG 126 61.3
R: TCTTCCTCTTGTGCTCTTGCTGG
PPAR-γ F: ATGACAGACCTCAGACAGATTG 210 54
R: AATGTTGGCAGTGGCTCAG
GLUT-1 F: TATCTGAGCATCGTGGCCAT 238 62.1
R: AAGACGTAGGGACCACACAG
LDLR F: ACTTACGGACAGACAGACAG 223 57
R: GGCCACACATCCCATGATTC
GAPDH, glyceraldehyde-3-Phosphate dehydrogenase; GLUT-1, glucose trans-
porter 1; LDLR, low-density lipoprotein receptor; PPAR-γ, peroxisome pro-
liferator-activated receptor gamma.
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Fig. 1. Summary of patient ﬂow diagram.
Table 2
General characteristics of study participantsa.
Placebo group (n=29) Melatonin group (n=29) Pb
Age (years) 26.0 ± 3.3 26.5 ± 3.5 0.59
Height (cm) 162.9 ± 5.2 163.0 ± 4.2 0.91
Weight at study baseline (kg) 73.7 ± 13.1 72.1 ± 12.9 0.63
Weight at end-of-trial (kg) 73.6 ± 12.3 71.9 ± 12.6 0.61
Weight change (kg) −0.1 ± 1.5 −0.2 ± 1.2 0.81
BMI at study baseline (kg/m2) 27.8 ± 4.7 27.1 ± 4.6 0.58
BMI at end-of-trial (kg/m2) 27.8 ± 4.7 27.1 ± 5.0 0.57
BMI change (kg/m2) −0.04 ± 0.6 −0.05 ± 0.5 0.92
a Data are means ± SDs.
b Obtained from independent t-test.
Table 3
Metabolic proﬁles at baseline and after the 12-week intervention in women with polycystic ovary syndrome that received either melatonin supplements or placeboa.
Variables Placebo group (n=29) Melatonin group (n=29) Diﬀerence in outcome measures between melatonin and placebo groupsa
Baseline Week 12 Baseline Week 12 β (95% CI) Pb
PSQI 7.7 ± 3.2 6.9 ± 3.3 8.1 ± 3.1 4.7 ± 2.1 −2.15 (−3.62, −0.68) 0.005
BDI score 21.7 ± 5.1 20.6 ± 5.1 22.1 ± 5.1 16.9 ± 3.6 −3.66 (−5.53, −1.78) <0.001
BAI score 17.1 ± 4.1 16.5 ± 4.8 18.9 ± 4.7 16.3 ± 4.4 −1.95 (−3.41, −0.48) 0.01
FPG (mg/dL) 93.9 ± 6.6 93.0 ± 7.5 94.9 ± 6.8 93.2 ± 5.5 −0.44 (−2.38, 1.50) 0.65
Insulin (μIU/mL) 11.8 ± 1.6 11.7 ± 2.0 13.3 ± 2.9 11.6 ± 2.8 −1.20 (−2.14, −0.26) 0.01
HOMA-IR 2.7 ± 0.5 2.7 ± 0.5 3.1 ± 0.8 2.7 ± 0.7 −0.28 (−0.50, −0.05) 0.01
QUICKI 0.329±0.007 0.329± 0.008 0.324± 0.012 0.332± 0.018 0.008 (0.002, 0.014) 0.007
Triglycerides (mg/dL) 147.8 ± 46.1 147.2 ± 46.9 149.5 ± 53.6 140.9 ± 54.4 −7.90 (−17.54, 1.72) 0.10
VLDL-cholesterol (mg/dL) 29.6 ± 9.2 29.4 ± 9.4 29.9 ± 10.7 28.2 ± 10.9 −1.58(−3.50, 0.34) 0.10
Total cholesterol (mg/dL) 177.7 ± 31.8 175.1 ± 28.9 179.9 ± 24.3 168.9 ± 22.7 −7.96 (−13.75, −2.17) 0.008
LDL-cholesterol (mg/dL) 100.5 ± 32.6 98.3 ± 29.6 106.9 ± 22.5 97.1 ± 20.9 −5.88 (−11.42, −0.33) 0.03
HDL-cholesterol (mg/dL) 47.7 ± 6.9 47.4 ± 7.0 43.9 ± 7.9 43.7 ± 7.9 −0.39 (−2.46, 1.67) 0.70
Total-/HDL-cholesterol ratio 3.8 ± 0.9 3.8 ± 0.9 4.2 ± 0.8 4.0 ± 0.8 −0.15 (−0.36, 0.05) 0.13
Data are mean ± SDs.
BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory; FPG, fasting plasma glucose; HOMA-IR, homeostasis model of assessment-insulin resistance; HDL-
cholesterol, high density lipoprotein-cholesterol; LDL-cholesterol, low density lipoprotein-cholesterol; PSQI, Pittsburgh Sleep Quality Index; QUICKI, quantitative
insulin sensitivity check index; VLDL-cholesterol, very low density lipoprotein-cholesterol.
a Outcome measures" refers to the change in values of measures of interest between baseline and week 12. β [diﬀerence in the mean outcomes measures between
treatment groups (melatonin group = 1 and placebo group = 0)].
b Obtained from multiple regression model (adjusted for baseline values of each biochemical variables, age and baseline BMI).
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melatonin intake (5mg/day) in subjects with delayed sleep phase
syndrome ameliorated depressive symptoms and sleep continuity.
However, 6 mg/day melatonin supplementation for 4 weeks did not
aﬀect mental health status in people with major depressive disorder
(Serfaty et al., 2010). Finally, melatonin administration did not impact
cognition and psychosocial functioning in subjects with severe mental
disorder (Baandrup et al., 2017).
4.2. Eﬀects on glycemic control and lipid proﬁles
We showed that melatonin supplementation to patients with PCOS
for 12 weeks signiﬁcantly decreased serum insulin levels, HOMA-IR,
total- and LDL-cholesterol levels, and signiﬁcantly increased QUICKI
score, while it did not inﬂuence FPG and other lipid proﬁles. In addi-
tion, melatonin intake up-regulated gene expression of PPAR-γ and
LDLR in PBMCs of women with PCOS, but did not aﬀect gene expres-
sion of GLUT-1. On the basis of existing evidence, melatonin adminis-
tration may have some beneﬁcial eﬀects on glucose homeostasis and
lipid proﬁles. Ewida et al.(2016) demonstrated that melatonin intake
(5mg/kg) in MetS rats for 6 weeks signiﬁcantly improved insulin re-
sistance and dyslipidemia (Ewida and Al-Sharaky, 2016). In addition,
melatonin intake in diabetic rats signiﬁcantly ameliorated hypertension
and insulin resistance and up-regulated PPAR-γ coactivator 1a and
GLUT-4 gene expression (Rahman et al., 2017). Recently, we docu-
mented that 10mg/day melatonin supplementation to diabetic people
with coronary artery disease for 12 weeks had favorable impacts on
glycemic control, insulin sensitivity, and HDL-cholesterol concentra-
tions (Raygan et al., 2017). Also, melatonin consumption at a daily
dosage of 10mg by patients with non-alcoholic fatty liver disease for 4
weeks signiﬁcantly decreased median value of HOMA-IR
(Gonciarz et al., 2013). In a meta-analysis, melatonin was shown to
have a signiﬁcant impact on triglycerides and total cholesterol con-
centrations, but did not aﬀect HDL- and LDL-cholesterol levels
(Mohammadi-Sartang et al., 2017). However, 6 mg/day melatonin ad-
ministration for 14 days increased VLDL-cholesterol concentrations, but
did not inﬂuence LDL- and HDL-cholesterol levels in postmenopausal
women (Wakatsuki et al., 2001). In addition, supplementation with
3mg/day of melatonin after 8 weeks did not inﬂuence glucose control
and insulin resistance in patients with schizophrenia
(Modabbernia et al., 2014). These varied results of diﬀerent studies
may be associated with the diﬀerences in the type of diseases, dosage of
melatonin consumption, and duration of the studies. A high-dose ad-
ministration of melatonin or a longer intervention in women with PCOS
may inﬂuence FPG, triglycerides, and HDL-cholesterol levels. Melatonin
receptors (MT1 and MT2) have been identiﬁed on the cells of adipose
cells and on the human pancreatic beta cells (Sharma et al., 2015).
Melatonin reportedly inhibits insulin release via two G-protein-coupled
receptors, MT1 (cAMP signaling pathway) and MT2 (cGMP signaling
pathway), which modulate glucose homeostasis (Contreras-
Alcantara et al., 2010). Furthermore, the favorable actions of melatonin
on lipid concentrations may be due to increased esteriﬁcation of cho-
lesterol (Esquiﬁno et al., 1997) mediated by higher lecithin-cholesterol
acyltransferase activity (Tamura et al., 2008).
We encountered a few limitations in the current investigation. Due
to budget limitations, we did not evaluate the eﬀects of melatonin
supplementation on serum and/or urinary melatonin. Secondly, we
were unable to determine the impact of melatonin administration on
expression other gene related to insulin and lipid metabolism.
4.3. Conclusions
Overall, melatonin supplementation for 12 weeks to PCOS women
who were candidates for IVF had beneﬁcial eﬀects on mental health
status, insulin levels, HOMA-IR, QUICKI, and gene expression of PPAR-
γ and LDLR, but did not inﬂuence other metabolic proﬁles and gene
expression of GLUT-1. This suggests melatonin supplementation may
confer advantageous therapeutic potential for women with PCOS.
Further research is needed in other participants and for longer periods
to determine the beneﬁcial eﬀects of melatonin supplementation.
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Fig. 2. Fold change (means ± SDs) in gene expression levels of PPAR-γ and
GLUT-1 in women with polycystic ovary syndrome receiving melatonin sup-
plements and placebo
P value was obtained from independent t-test. N= 29 in each group.
Fig. 3. Fold change (means ± SDs) in gene expression levels of LDLR in
women with polycystic ovary syndrome receiving melatonin supplements and
placebo
P value was obtained from independent t-test. N= 29 in each group.
GLUT-1, glucose transporter 1; LDLR, low-density lipoprotein receptor; PPAR-γ,
peroxisome proliferator-activated receptor gamma; PCOS, polycystic ovary
syndrome; PBMCs, peripheral blood mononuclear cells.
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